Biohaven Pharmaceutical Holding ROE 2016-2022 | BHVN

Current and historical return on equity (ROE) values for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Biohaven Pharmaceutical Holding ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-03-31 $-0.79B $-0.47B 140.19%
2021-12-31 $-0.85B $-0.74B 163.75%
2021-09-30 $-0.87B $-0.59B 201.63%
2021-06-30 $-0.89B $-0.46B 265.18%
2021-03-31 $-0.86B $-0.28B 373.88%
2020-12-31 $-0.77B $-0.39B 591.14%
2020-09-30 $-0.70B $-0.21B 2198.43%
2020-06-30 $-0.61B $-0.04B -1182.52%
2020-03-31 $-0.64B $0.12B -597.20%
2019-12-31 $-0.53B -524.07%
2019-09-30 $-0.43B $0.12B -313.36%
2019-06-30 $-0.39B $0.19B -310.58%
2019-03-31 $-0.22B $0.10B -200.46%
2018-12-31 $-0.24B $0.15B -216.22%
2018-09-30 $-0.21B $0.07B -199.53%
2018-06-30 $-0.19B $0.12B -150.68%
2018-03-31 $-0.20B $0.11B -136.50%
2017-12-31 $-0.14B $0.13B -110.98%
2017-09-30 $-0.14B $0.16B -150.41%
2017-06-30 $-0.12B $0.19B -233.18%
2017-03-31 $-0.08B $0.02B -1866.67%
2016-12-31 $-0.06B $-0.00B 12800.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.248B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00